dspp wrote:You may be surprised. They are at the personal end of the spectrum. However I would sell and rinse if I were you, perhaps by staging within something similar but not exactly the same. regards, dspp
Thanks. I was in contact with three advisors recently, with a view to sorting out the best account/tax structure for the future, before I relo back into the UK, but the 'pre' ID requirements, even before getting some suggestions floated, led me to give up. Once I'm back though, I am going to get tax-efficiency [etc] sorted out for good, so will be coming back to this topic in future.
I've considered selling and re-investing in the same sector, I'll look into this today, AZN is the obvious parallel to GSK in the pharma sector, but I'll approach it with a blank sheet and see what comes up. Another option is re-investing via top-ups across existing holdings, well, ones that currently appear robust. I'll see how it looks. ...Or an outright new 'chip' in a new sector, but it'd have to screaming at me pretty clearly for that I think.
I wonder if the 30-day sale>repurchase rule even applies if you're non-resident. Ah well, I suppose the IR are achieving what they perhaps intended, not understanding their rules, so we gold-plate what we fear they might be.
p.s. re: 'similar but not the same' - there's a thought, wonder if there is any mileage in switching into the ADR's - or if that would open up it's own IRS/tax issue. I'll see...